This is a rare type of cancer that starts in the nerves under the skin. It grows quickly and can spread to other parts of the body. It often happens in children and is linked to a condition called Neurofibromatosis 1.
Every report comes from a Lived member, sent anonymously.
Have you had Surgery for Neurofibrosarcoma?
Neurofibrosarcoma, now usually called malignant peripheral nerve sheath tumor (MPNST), is a rare cancer that starts in the protective sheath wrapped around a nerve. It affects peripheral nerves, the ones outside the brain and spinal cord, and most often appears in the arms, legs, trunk or deep in the back of the abdomen. It is a type of sarcoma, a cancer of the body's soft and connective tissues. MPNST tends to grow quickly, can come back after treatment and can spread to other parts of the body. Because it grows on a nerve, it can cause pain, weakness or numbness as well as a lump. It is different from neurofibromas and schwannomas, which are also nerve sheath tumors but are benign. That distinction matters most for people with neurofibromatosis type 1, who often live with many benign nerve tumors.
The strongest known risk factor is neurofibromatosis type 1 (NF1), an inherited condition that causes benign tumors to grow along nerves. Roughly a quarter to half of people with MPNST have NF1, and an estimated 8 to 13 percent of people with NF1 develop MPNST during their lifetime. In NF1, the cancer often arises from a plexiform neurofibroma, a larger benign tumor that runs along a nerve, sometimes passing through an in-between stage that pathologists call an atypical neurofibroma. MPNST linked to NF1 tends to appear earlier, often between ages 25 and 35, while MPNST in people without NF1 usually appears around age 50. Radiation treatment for an earlier cancer is another recognized risk; these tumors can arise in the treated area decades later. Many people with MPNST have neither NF1 nor past radiation, and researchers do not yet know what triggers it in those cases.
Assessment usually starts with a lump that is growing, painful or affecting nerve function. MRI is the main imaging test because it shows the tumor's size, its relationship to nearby nerves and features that raise suspicion, such as areas of dead tissue or bleeding inside it. CT scans can help when MRI is not possible or to check bone, and a PET scan, which highlights tissue that is using a lot of energy, can help pick out the most active part of a tumor and look for spread. A biopsy is needed to confirm the diagnosis. A small sample, usually taken with a needle, is examined by a pathologist with sarcoma experience, because MPNST can look like other sarcomas and, in NF1, like a benign or atypical neurofibroma. Further scans then show whether the cancer has spread, which shapes the treatment plan.
MPNST is treated as a high-grade sarcoma, ideally by a team at a center that sees many sarcomas. Surgery to remove the whole tumor with a rim of healthy tissue around it (a clear margin) is the main treatment and the only one that offers a chance of cure. Whether the margins are clear is the strongest single predictor of outcome, so surgeons sometimes have to remove part of the affected nerve, which can leave lasting weakness or numbness. Limb-sparing surgery is preferred when clear margins are possible; amputation is reserved for situations where it is not. Radiation is often given before or after surgery to lower the chance of the tumor coming back in the same place, especially for large or high-grade tumors. It has not been shown to lengthen survival, and for people with NF1 it is weighed more carefully because they have a higher risk of new cancers caused by radiation. Chemotherapy is not routinely given after a complete operation, though it may be considered for large, high-risk tumors or to shrink one that is hard to remove. When MPNST cannot be removed or has spread, the usual first treatment is doxorubicin, a chemotherapy drug, often combined with ifosfamide. It shrinks the tumor in roughly one in five people and usually controls the disease for months rather than years; tumors linked to NF1 respond less often. Targeted drugs and immunotherapy are mainly available through clinical trials, which specialists actively encourage for this cancer. Palliative care, which focuses on pain and other symptoms, can be part of treatment at any stage.
Outlook varies widely. Estimates of five-year survival range from about 23 to 69 percent, depending mostly on the tumor's size and location, whether it has spread and whether surgery removed it completely. Smaller tumors in the limbs that are fully removed generally do best; tumors deep in the trunk, those linked to NF1 or past radiation, and those that have spread carry a harder outlook. Recovery depends on the operation. Losing part of a nerve can mean physical therapy, braces or adapting how certain tasks are done. Because MPNST often returns, follow-up continues for years, with regular exams and scans to check the original site and look for spread elsewhere. People with NF1 also continue routine care for their other nerve tumors, ideally through a specialized NF1 clinic.
See a doctor about any lump that is growing, especially one that is painful or causes weakness or numbness in the area the nerve supplies. For people with NF1, contact the care team promptly if a known neurofibroma becomes persistently or increasingly painful, grows quickly or changes in firmness, or if new weakness, numbness or loss of function appears. After treatment, report new lumps near the surgical site, new or returning pain, or other new symptoms that do not settle, rather than waiting for the next scheduled visit.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Neurofibrosarcoma is like, what's helped you, or ask the community a question.